ArticleBMC cancer2018

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.

Volkmar Müller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.